Photo by jluis_zz from unsplash
INTRODUCTION AND OBJECTIVE:Vibegron is a novel, once-daily, oral β3-adrenoceptor agonist under development for treatment of OAB. In the phase 3, randomized, double-blind, placebo- and active-contro... Click to show full abstract
INTRODUCTION AND OBJECTIVE:Vibegron is a novel, once-daily, oral β3-adrenoceptor agonist under development for treatment of OAB. In the phase 3, randomized, double-blind, placebo- and active-contro...
Keywords:
overactive bladder;
efficacy daily;
pd21 efficacy;
daily vibegron;
vibegron overactive;
vibegron
Journal Title: Journal of Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!